A Study of a Personalized Neoantigen Cancer Vaccine

Inclusion Criteria:

• Provide a signed and dated informed consent form prior to initiation of study-specificprocedures.
• Patients with the indicated advanced or metastatic solid tumor as follows:

1. NSCLC who are planned for or have received no more than 1 cycle of systemictreatment with cytotoxic, platinum-based chemotherapy (note: patients who havereceived anti-PD-(L)1 monotherapy are eligible)
2. GEA who are planned for or have received no more than 1 cycle of systemictreatment with cytotoxic, platinum-based chemotherapy
3. mUC who are planned for or have received no more than 1 cycle of systemictreatment with cytotoxic, platinum-based chemotherapy
4. CRC-MSS who are receiving first line systemic therapy or who are planned for orhave received no more than 1 cycle of second line systemic therapy including afluoropyrimidine and oxaliplatin or irinotecan

• 18 years of age or older
• ECOG Performance Status 0 or 1
• Lesion amenable to biopsy
• Measurable disease according to RECIST v1.1
• Have adequate organ function, as measured by laboratory values (criteria listed inprotocol)

Exclusion Criteria:

• Tumors with genetic characteristics as follows:

1. For NSCLC, patients with a known genetic driver alteration in EGFR, ALK, ROS1,RET, or TRK
2. For CRC and GEA, patients with known MSI-high disease based on institutionalstandard
3. For CRC, patients with a known BRAF V600E mutation or patients with peritonealcarcinomatosis and for GEA, patients with peritoneal carcinomatosis as their onlyevidence of disease

• Patients with known central nervous system (CNS) metastases and/or carcinomatousmeningitis
• Known exposure to chimpanzee adenovirus or any history of anaphylaxis in reaction to avaccination or allergy or hypersensitivity to study drug components
• Bleeding disorder (eg., factor deficiency, coagulopathy) or history of significantbruising or bleeding following IM injections or blood draws Complete inclusion and exclusion criteria are listed in the clinical study protocol.